You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Solving Sepsis: Early Identification and Prompt Management Using Machine Learning

    SBC: Cohere-Med, Inc.            Topic: 300

    Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease

    SBC: Metselex, Incorporated            Topic: 105

    ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Automated Mental Health Referral System

    SBC: MiResource, Inc.            Topic: 104

    This proposal addresses a significant barrier to obtaining treatment for college-ageyouth with mental disorders. Many college-age youth with impairing mental disordersremain untreated because of concerns about stigma and privacy, inconvenience and wait times, andbecause universities are often unable to service all such students. Also, of critical importance,when referral for treatment is implement ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A digital tool for monitoring speech decline in ALS

    SBC: MODALITY.AI , INC            Topic: NIDCD

    PROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: 102

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Bio-tissue Oxygenation Nanophosphor Enabled Sensing (BONES) system for Quantifying Hypoxia in Bone Marrow

    SBC: SIGRAY, INC.            Topic: 400

    Project Summary/Abstract Low oxygen (hypoxic) environments are known to be important for maintaining the small number of adult stem cells in the human body, such as in bone marrow. These conditions are also believed to enable dormant cancer cells to survive and metastasize years or decades after the original tumor has been destroyed and the reason why bone marrow is one of the most common sites of ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Care Assistant for Family Caregivers of Persons with Dementia During Out of the Home Activities

    SBC: Koronis Biomedical Technologies Corp.            Topic: R

    Abstract Increases in life expectancy together with demographic trends have fueled a rapid increase in America’s elderly population. As the number of older Americans has grown, so has the prevalence of aging-associated diseases, including Alzheimer’s Disease (AD) and other related dementias (ADRD). An estimated 5.4 Million Americans had AD in 2012, and that number is expected to double by 2030 ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution

    SBC: Fluid Discovery Inc            Topic: 400

    Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, rema ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government